2 results match your criteria: "Fondazione PTV - Tor Vergata University Hospital[Affiliation]"
Clinical trial eligibility in PSP: Population representativeness and potential criteria adjustment based on PSP-NET findings.
Parkinsonism Relat Disord
December 2024
Neurology Unit and Neurobiorepository and Laboratory of Advanced Biological Markers, Department of Clinical and Experimental Sciences, University of Brescia, And Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy.
Background: Progressive Supranuclear Palsy (PSP) is a rare, heterogeneous neurodegenerative disease for which no treatment is currently available. In the context of clinical trials, the representativeness of the included patients is crucial for the generalizability of the results. Herein, we present results from a multicenter perspective study to identify the most restrictive criteria for patient selection and to assess the representativeness of eligible patients.
View Article and Find Full Text PDFImmunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy.
Mov Disord
December 2024
Neurology Unit, Fondazione PTV - Tor Vergata University Hospital, Rome, Italy.
Background: Peripheral immune cells critically contribute to the clinical-pathological progression of neurodegenerative diseases and also represent a reliable frame for translational applications. However, data on progressive supranuclear palsy (PSP) are almost scarce in this regard.
Objective: Our goal is to provide a broad biological characterization of peripheral immune cells in a selected PSP cohort.